|
2011 Conference Publication A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosisMollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S. (2011). A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), San Diego, CA, United States, Dec 10-13, 2011. Washington, DC, United States: American Society of Hematology. |
|
2011 Conference Publication Analytical aspects of standardised protein electrophoresis and immunofixation reportingTate, Jill, for the Working Party on Standardised Reporting of Protein Electrophoresis, Mollee, Peter, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard and Wienholt, Louise (2011). Analytical aspects of standardised protein electrophoresis and immunofixation reporting. 35th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology, Sydney, NSW Australia, 4-6 June 2010. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0031-3025(16)33167-1 |
|
2011 Journal Article Treatment of acute promyelocytic leukaemia in the Jehovah's Witness populationKeane, Colm, Mollee, Peter, Marlton, Paula and Gill, Devinder (2011). Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Annals of Hematology, 90 (3), 359-360. doi: 10.1007/s00277-010-1023-0 |
|
2010 Conference Publication WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidationGray, James X., McMillen, Lyle, Saal, Russell, Lane, Steven, Bird, Robert, Gill, Devinder, Mollee, Peter and Marlton, Paula (2010). WT1 Expression as a marker of minimal residual disease, predicts outcome in acute myeloid leukaemia when measured at post-consolidation. Royal College of Pathologists of Australasia Pathology Update, Melbourne, VIC Australia, 26-28 February 2010. Oxford, United Kingdom: Elsevier. doi: 10.1097/01268031-201042001-00118 |
|
2010 Conference Publication Survival and prognostic factors amongst Australian patients with AL amyloidosisMollee, P, Tate, J, Morris, K, Wellwood, J, Browne, M, Marlton, P, Bird, R, Mills, AK, Wood, P, Mapp, S and Gill, D (2010). Survival and prognostic factors amongst Australian patients with AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome Italy, Apr 18-21, 2010. LONDON: INFORMA HEALTHCARE. |
|
2010 Conference Publication Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosisMollee, P., Tate, J., Weiss, D. and Solomon, A. (2010). Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody-based Freelite assay in AL amyloidosis. 12th International Symposium on Amyloidosis from Molecular Mechanisms Toward the Cure of Systemic Amyloidoses, Rome, Italy, 18-21, April 2010. London, United Kingdom: Informa Healthcare. |
|
2010 Book Chapter Myeloablative allogeneic stem cell transplantation for non-Hodgkin's lymphomaKuruvilla, J., Mollee, P. and Lipton, J. H. (2010). Myeloablative allogeneic stem cell transplantation for non-Hodgkin's lymphoma. Allogeneic stem cell transplantation. (pp. 89-108) edited by Lazarus, HM and Laughlin, MJ. Totowa, NJ, United States: Humana Press. doi: 10.1007/978-1-59745-478-0_7 |
|
2009 Conference Publication Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort studyMollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. 51st ASH Annual Meeting, New Orleans, LA United States, 5–8 December 2009. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v114.22.1382.1382 |
|
2009 Conference Publication WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)Gray, James X, McMillen, Lyle, Saal, Russell, Lane, Steven, Mollee, Peter, Bird, Robert, Gill, Devinder and Marlton, Paula (2009). WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML). 51st ASH Annual Meeting, New Orleans, LA, 5-8 December 2009. American Society of Hematology. doi: 10.1182/blood.v114.22.2639.2639 |
|
2009 Journal Article Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathiesMollee, Peter (2009). Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clinical Biochemist Reviews, 30 (3), 93-103. |
|
2009 Journal Article Monoclonal Gammopathies – Clinical and Laboratory IssuesTate, Jill, Mollee, Peter and Johnson, R. (2009). Monoclonal Gammopathies – Clinical and Laboratory Issues. Clinical Biochemist Reviews, 30 (3), 89-91. |
|
2009 Journal Article Quantitative serum free light chain assay--analytical issuesTate, Jill, Bazeley, Sheree, Sykes, Stephen and Mollee, Peter (2009). Quantitative serum free light chain assay--analytical issues. The Clinical biochemist. Reviews, 30 (3), 131-40. doi: 10.1186/1471-2369-9-11 |
|
2009 Journal Article Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory StatesMarshall, George, Tate, Jill and Mollee, P. (2009). Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory States. American Journal of Clinical Pathology, 132 (2), 309-309. doi: 10.1309/AJCP8VOT5TVLAQBQ |
|
2009 Journal Article Quantitative serum free light chain assay: Analytical issuesTate, Jill, Bazeley, Sheree, Sykes, Stephen and Mollee, Peter (2009). Quantitative serum free light chain assay: Analytical issues. Clinical Biochemist Reviews, 30 (3), 131-140. |
|
2009 Journal Article Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantationHall, S. L., Tate, J., Gill, D. and Mollee, P. (2009). Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clinical Biochemist Reviews, 30 (3), 113-118. |
|
2009 Conference Publication Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort studyMollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. 51st ASH Annual Meeting and Exposition, New Orleans, LA, U.S.A., 5-8 December 2009. Washington, DC, U.S.A.: American Society of Hematology. |
|
2009 Conference Publication WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)Gray, J. X., McMillen, L., Saal, R., Lane, S., Mollee, P., Bird, R., Gill, D. and Marlton, P. (2009). WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML). 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5-8 December 2009. Washington, DC, United States: American Society of Hematology. |
|
2009 Conference Publication Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trialTrappe, Ralf, Choquet, Sylvain, Oertel, Stephan H.K., Leblond, Veronique, Dierickx, Daan, Mollee, Peter, Sender, Monica, Ekman, Tor, Zaucha, Jan Maciej, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Dreyling, Martin H., Duhrsen, Ulrich, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Anagnostopoulos, Ioannis, Raphael, Martine, Dorken, Bernd and Riess, Hanno (2009). Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5 - 8 December 2009. Washington, DC, United States: American Society of Hematology. |
|
2008 Conference Publication Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitroGill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.3157.3157 |
|
2008 Conference Publication Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) populationKeane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014 |
